Panacea Biotec Limited (NSE:PANACEABIO)

Panacea Biotec Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Cash & Equivalents	-	821.25	471.74	398.52	503.5	520.79
Short-Term Investments	-	440.91	638.99	1,598	4,963	390.99
Trading Asset Securities	-	31.53	403.62	134.16	50.01	-
Cash & Short-Term Investments	1,101	1,294	1,514	2,130	5,516	911.78
Cash Growth	-38.77%	-14.57%	-28.92%	-61.38%	505.00%	74.95%
Accounts Receivable	-	725.57	574.19	600.92	816.56	846.84
Other Receivables	-	11.58	10.57	12.02	10.58	63.42
Receivables	-	762.82	618.08	628.74	841.54	930.21
Inventory	-	2,137	1,779	2,021	2,127	1,741
Prepaid Expenses	-	71.08	60.63	52.2	53.49	52.87
Other Current Assets	-	1,187	882.26	850.84	1,367	1,473
Total Current Assets	-	5,452	4,855	5,683	9,906	5,110
Property, Plant & Equipment	-	6,369	6,348	6,163	6,255	6,279
Long-Term Investments	-	1.17	1.72	1.74	803.91	5.52
Other Intangible Assets	-	360.91	276.32	153.3	132.36	139.71
Long-Term Deferred Tax Assets	-	-	-	-	237.51	1.47
Long-Term Deferred Charges	-	61.71	83.66	106.11	5.88	12.5
Other Long-Term Assets	-	652.84	843.43	600.99	248.48	227.46
Total Assets	-	12,897	12,408	12,712	17,589	11,775
Accounts Payable	-	2,258	1,456	1,773	2,347	2,467
Accrued Expenses	-	369.66	439.6	361.43	404.63	381.76
Short-Term Debt	-	-	-	0.55	-	-
Current Portion of Long-Term Debt	-	-	-	-	0.52	844.46
Current Income Taxes Payable	-	0.08	1.35	5.6	0.85	0.26
Current Unearned Revenue	-	17.69	171.03	196.62	-	-
Other Current Liabilities	-	1,025	1,022	980.88	5,010	797.87
Total Current Liabilities	-	3,670	3,090	3,318	7,764	4,491
Long-Term Debt	-	222.06	209.94	201.64	341.03	7,351
Long-Term Unearned Revenue	-	108.52	218.46	321.39	455.88	29.06
Long-Term Deferred Tax Liabilities	-	232.82	225.45	203.71	-	-
Other Long-Term Liabilities	-	166.91	117.78	131.22	147.3	2,049
Total Liabilities	-	4,591	4,026	4,311	8,852	14,092
Common Stock	-	61.25	61.25	61.25	61.25	61.25
Additional Paid-In Capital	-	919.4	919.4	919.4	919.4	919.4
Retained Earnings	-	8,594	8,678	8,694	9,041	-1,745
Comprehensive Income & Other	-	-1,443	-1,455	-1,455	-1,472	-1,739
Total Common Equity	8,348	8,131	8,204	8,219	8,550	-2,503
Minority Interest	-	-41.7	-38.21	-34.89	-29.81	-30
Shareholders' Equity	8,306	8,306	8,382	8,401	8,737	-2,317
Total Liabilities & Equity	-	12,897	12,408	12,712	17,589	11,775
Total Debt	222.1	222.06	209.94	202.19	341.55	8,195
Net Cash (Debt)	879.1	1,072	1,304	1,928	5,175	-7,283
Net Cash Growth	-44.66%	-17.85%	-32.35%	-62.74%	-	-
Net Cash Per Share	14.37	17.50	21.30	31.48	84.48	-118.91
Filing Date Shares Outstanding	61.36	61.25	61.25	61.25	61.25	61.25
Total Common Shares Outstanding	61.36	61.25	61.25	61.25	61.25	61.25
Working Capital	-	1,782	1,765	2,365	2,142	618.81
Book Value Per Share	136.92	132.75	133.94	134.19	139.59	-40.87
Tangible Book Value	7,925	7,770	7,928	8,066	8,417	-2,643
Tangible Book Value Per Share	129.99	126.86	129.43	131.69	137.43	-43.15
Land	-	2,068	2,059	2,059	2,027	1,773
Buildings	-	3,155	3,196	3,333	3,333	3,286
Machinery	-	6,624	6,442	6,509	6,512	6,258
Construction In Progress	-	935.13	747.15	280.07	49.12	212.41

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.